(NASDAQ: VIGL) Vigil Neuroscience's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 38.94%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.52%.
Vigil Neuroscience's revenue in 2024 is $0.On average, 1 Wall Street analysts forecast VIGL's revenue for 2025 to be $1,740,589,559, with the lowest VIGL revenue forecast at $1,740,589,559, and the highest VIGL revenue forecast at $1,740,589,559. On average, 1 Wall Street analysts forecast VIGL's revenue for 2026 to be $5,115,909,554, with the lowest VIGL revenue forecast at $5,115,909,554, and the highest VIGL revenue forecast at $5,115,909,554.
In 2027, VIGL is forecast to generate $4,653,375,266 in revenue, with the lowest revenue forecast at $1,933,865,450 and the highest revenue forecast at $7,372,885,082.